Share on StockTwits
 

Stock analysts at Ladenburg Thalmann reduced their price objective on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $138.00 to $135.00 in a report issued on Wednesday, Analyst Ratings Network reports. The firm currently has a “buy” rating on the stock. Ladenburg Thalmann’s price target points to a potential upside of 34.33% from the company’s current price.

A number of other analysts have also recently weighed in on UTHR. Analysts at RBC Capital raised their price target on shares of United Therapeutics Corp. from $80.00 to $90.00 in a research note on Wednesday. They now have a “sector perform” rating on the stock. Separately, analysts at Zacks upgraded shares of United Therapeutics Corp. from a “neutral” rating to an “outperform” rating in a research note on Friday, January 24th. They now have a $135.00 price target on the stock. Finally, analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $92.43.

United Therapeutics Corp. (NASDAQ:UTHR) traded down 0.42% during mid-day trading on Wednesday, hitting $100.08. 457,003 shares of the company’s stock traded hands. United Therapeutics Corp. has a 1-year low of $56.85 and a 1-year high of $116.65. The stock’s 50-day moving average is $105.0 and its 200-day moving average is $90.44. The company has a market cap of $5.027 billion and a price-to-earnings ratio of 18.26.

United Therapeutics Corp. (NASDAQ:UTHR) last released its earnings data on Tuesday, February 25th. The company reported $2.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $1.37. The company had revenue of $289.02 million for the quarter, compared to the consensus estimate of $295.43 million. Analysts expect that United Therapeutics Corp. will post $7.09 EPS for the current fiscal year.

In other United Therapeutics Corp. news, COO Roger Jeffs sold 10,000 shares of the stock on the open market in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $104.89, for a total value of $1,048,900.00. Following the transaction, the chief operating officer now directly owns 897 shares of the company’s stock, valued at approximately $94,086. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.